BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475]
URL: https://www.wjgnet.com/1007-9327/full/v20/i13/3475.htm
Number Citing Articles
1
Paula Sousa, Paula Ministro, Alessandro Armuzzi, Axel Dignass, Marte Lie Høivik, Manuel Barreiro-de Acosta, Stephan Vavricka, Rogério Saad-Hossne, Paulo Gustavo Kotze, Laurent Peyrin-Biroulet, Fernando Magro. Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel diseaseDigestive and Liver Disease 2021; 53(12): 1571 doi: 10.1016/j.dld.2021.05.038
2
M Cavaco, J Goncalves. Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and VictimsClinical Pharmacology & Therapeutics 2017; 102(4): 649 doi: 10.1002/cpt.605
3
William J. Sandborn, Douglas C. Wolf, Gordana Kosutic, Gerry Parker, Stefan Schreiber, Scott D. Lee, Bincy Abraham, Anita Afzali, Razvan I. Arsenescu, Alexandra Gutierrez, Marshall Spearman, Jason Coarse, Brian G. Feagan. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab PegolInflammatory Bowel Diseases 2017; 23(7): 1047 doi: 10.1097/MIB.0000000000001100
4
Marla C. Dubinsky, Becky L. Phan, Namita Singh, Shervin Rabizadeh, Diane R. Mould. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD PatientsThe AAPS Journal 2017; 19(1): 215 doi: 10.1208/s12248-016-9994-y
5
Robert A. Mitchell, Constantin Shuster, Neal Shahidi, Cherry Galorport, Mari L. DeMarco, Gregory Rosenfeld, Robert A. Enns, Brian Bressler. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World ExperienceCanadian Journal of Gastroenterology and Hepatology 2016; 2016: 1 doi: 10.1155/2016/5203898
6
Maria A.V. Willrich, David L. Murray, Melissa R. Snyder. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseasesTranslational Research 2015; 165(2): 270 doi: 10.1016/j.trsl.2014.09.006
7
Laura Wilson, Stephanie Tuson, Lufang Yang, Dustin Loomes. Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel DiseaseJournal of the Canadian Association of Gastroenterology 2021; 4(3): 101 doi: 10.1093/jcag/gwaa005
8
Vu Q. Nguyen, Kristin Eden, Holly A. Morrison, Megan B. Sammons, Kristin K. Knight, Siena Sorrentino, Rebecca M. Brock, Douglas J. Grider, Irving C. Allen, Dario Sorrentino. Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF AgentsFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.655887
9
Qianhui Zou, Xin Zhang, Xiaoshuang Liu, Yitong Li, Qiaoli Tan, Qin Dan, Tian Yuan, Xuebo Liu, Rui Hai Liu, Zhigang Liu. Ficus caricapolysaccharide attenuates DSS-induced ulcerative colitis in C57BL/6 miceFood & Function 2020; 11(7): 6666 doi: 10.1039/D0FO01162B
10
María López-Ibáñez, Ignacio Marín-Jiménez. Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel diseaseGastroenterología y Hepatología (English Edition) 2016; 39(4): 265 doi: 10.1016/j.gastre.2016.03.003
11
Polina Zalizko, Juris Stefanovics, Jelizaveta Sokolovska, Natalia Paramonova, Evija Klavina, Renars Erts, Vita Rovite, Janis Klovins, Aldis Pukitis. Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian populationTherapeutic Advances in Gastroenterology 2020; 13: 175628482093742 doi: 10.1177/1756284820937426
12
Carlos Fernandes, Mariangela Allocca, Silvio Danese, Gionata Fiorino. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel diseaseImmunotherapy 2015; 7(2): 175 doi: 10.2217/imt.14.105
13
Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn, Niels Vande Casteele. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBDInflammatory Bowel Diseases 2015; 21(1): 182 doi: 10.1097/MIB.0000000000000202
14
Graham Cope. Managing ulcerative colitis and Crohn's diseaseNursing and Residential Care 2014; 16(12): 687 doi: 10.12968/nrec.2014.16.12.687
15
Marla C. Dubinsky. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitisPostgraduate Medicine 2017; 129(5): 538 doi: 10.1080/00325481.2017.1319730
16
Mohammad F. Rabbi, Nour Eissa, Peris M. Munyaka, Laëtitia Kermarrec, Omar Elgazzar, Ehsan Khafipour, Charles N. Bernstein, Jean Eric Ghia. Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut MicrobiotaFrontiers in Immunology 2017; 8 doi: 10.3389/fimmu.2017.00985
17
Yoko Yokoyama, Kenji Watanabe, Hiroaki Ito, Masakazu Nishishita, Koji Sawada, Yusuke Okuyama, Kazuichi Okazaki, Hisao Fujii, Hiroshi Nakase, Tsutomu Masuda, Ken Fukunaga, Akira Andoh, Shiro Nakamura. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter studyCytotherapy 2015; 17(5): 680 doi: 10.1016/j.jcyt.2015.02.007
18
Carlos Taxonera, Marisa Iborra, Marta Maia Bosca-Watts, Saioa Rubio, Óscar Nantes, Rebeca Higuera, Federico Bertoletti, Pilar Martínez-Montiel, Mónica Sierra-Ausin, Noemí Manceñido, José Lázaro Pérez-Calle, Alicia Algaba, David Olivares, Cristina Alba. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitisCurrent Medical Research and Opinion 2019; 35(7): 1297 doi: 10.1080/03007995.2019.1579557
19
Tomasz J. Ślebioda, Zbigniew Kmieć. Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel DiseaseMediators of Inflammation 2014; 2014: 1 doi: 10.1155/2014/325129
20
Cindy C. Y. Law, Saranya Sasidharan, Rodrigo Rodrigues, Deanna D. Nguyen, Jenny Sauk, John Garber, Cosmas Giallourakis, Ramnik Xavier, Hamed Khalili, Vijay Yajnik, Ashwin N. Ananthakrishnan. Impact of Specialized Inpatient IBD Care on Outcomes of IBD HospitalizationsInflammatory Bowel Diseases 2016; 22(9): 2149 doi: 10.1097/MIB.0000000000000870
21
James Akingbasote, Sandra Szlapinski, Elora Hilmas, Patrik Miller, Natalie Rine. Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology2022; : 197 doi: 10.1007/978-3-031-12398-6_13
22
JAIME LUBASCHER C.. ERRORES FRECUENTES EN EL DIAGNÓSTICO Y TRATAMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINALRevista Médica Clínica Las Condes 2015; 26(5): 663 doi: 10.1016/j.rmclc.2015.08.004
23
Sophie Steeland, Leen Puimège, Roosmarijn E. Vandenbroucke, Filip Van Hauwermeiren, Jurgen Haustraete, Nick Devoogdt, Paco Hulpiau, Geert Leroux-Roels, Debby Laukens, Philip Meuleman, Martine De Vos, Claude Libert. Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1Journal of Biological Chemistry 2015; 290(7): 4022 doi: 10.1074/jbc.M114.617787
24
Marco Pelin, Elena Genova, Laura Fusco, Monzer Marisat, Ute Hofmann, Diego Favretto, Marianna Lucafò, Andrea Taddio, Stefano Martelossi, Alessandro Ventura, Gabriele Stocco, Matthias Schwab, Giuliana Decorti. Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assayChemico-Biological Interactions 2017; 275: 189 doi: 10.1016/j.cbi.2017.08.009
25
Ana Casajús, Pablo Zubiaur, Marta Méndez, Diana Campodónico, Antía Gómez, Marcos Navares-Gómez, Gonzalo Villapalos-García, Paula Soria-Chacartegui, Jesús Novalbos, Manuel Román, Gina Mejía-Abril, Dolores Ochoa, Francisco Abad-Santos. Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal MetabolizersAdvances in Therapy 2022; 39(4): 1743 doi: 10.1007/s12325-022-02067-8
26
María López-Ibáñez, Ignacio Marín-Jiménez. Niveles de fármaco y anticuerpos antifármaco en el manejo clínico del paciente con enfermedad inflamatoria intestinalGastroenterología y Hepatología 2016; 39(4): 265 doi: 10.1016/j.gastrohep.2015.09.012
27
Dario Sorrentino, Vu Nguyen, Carl Henderson, Adegabenga Bankole. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated DiseasesInflammatory Bowel Diseases 2016; 22(10): 2527 doi: 10.1097/MIB.0000000000000867
28
Shiyang Li, Wei Guo, Meichao Zhang, Mingyong Zeng, Haohao Wu. Microalgae polysaccharides exert antioxidant and anti-inflammatory protective effects on human intestinal epithelial cells in vitro and dextran sodium sulfate-induced mouse colitis in vivoInternational Journal of Biological Macromolecules 2024; 254: 127811 doi: 10.1016/j.ijbiomac.2023.127811
29
M. V. Matsievich, A. O. Bueverov, M. Yu. Petrachenkova. Alternative treatment regimens in autoimmune hepatitis: how justified is their choice?Almanac of Clinical Medicine 2018; 46(5): 504 doi: 10.18786/2072-0505-2018-46-5-504-513
30
Eugènia Santacana, Lorena Rodríguez-Alonso, Ariadna Padullés, Jordi Guardiola, Francisco Rodríguez-Moranta, Katja Serra, Jordi Bas, Francisco Morandeira, Biology, Helena Colom, Núria Padullés. External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel DiseaseTherapeutic Drug Monitoring 2018; 40(1): 120 doi: 10.1097/FTD.0000000000000476
31
David Olivares, Cristina Alba, Irene Pérez, Valentín Roales, Enrique Rey, Carlos Taxonera. Differences in the need for adalimumab dose optimization between Crohn�s disease and ulcerative colitisRevista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.6148/2018
32
Shivani Deswal, Anshu Srivastava. Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A ReviewJournal of Clinical and Experimental Hepatology 2017; 7(1): 55 doi: 10.1016/j.jceh.2017.01.115
33
Ronaldo Teixeira da Silva Júnior, Jonathan Santos Apolonio, Jessica Oliveira de Souza Nascimento, Bruna Teixeira da Costa, Luciano Hasimoto Malheiro, Marcel Silva Luz, Lorena Sousa de Carvalho, Cleiton da Silva Santos, Fabrício Freire de Melo. Crohn's disease and clinical management today: How it does?World Journal of Methodology 2023; 13(5): 399-413 doi: 10.5662/wjm.v13.i5.399
34
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel. Ulcerative colitisThe Lancet 2017; 389(10080): 1756 doi: 10.1016/S0140-6736(16)32126-2
35
Tomer Adar, Shimon Shteingart, Ami Ben-Ya’acov, Ariella Bar-Gill Shitrit, Dan M. Livovsky, Shimrit Shmorak, Mahmud Mahamid, Bernardo Melamud, Fiona Vernea, Eran Goldin. The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic ImplicationsDigestive Diseases and Sciences 2016; 61(7): 1915 doi: 10.1007/s10620-016-4047-z
36
Timur Liwinski, Christoph Schramm. Autoimmune hepatitis — update on clinical management in 2017Clinics and Research in Hepatology and Gastroenterology 2017; 41(6): 617 doi: 10.1016/j.clinre.2017.07.002
37
Scott D. Lee, Raina Shivashankar, Daniel Quirk, Haiying Zhang, Jean-Baptiste Telliez, John Andrews, Amy Marren, Arnab Mukherjee, Edward V. Loftus. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease TreatmentsJournal of Clinical Gastroenterology 2021; 55(3): 195 doi: 10.1097/MCG.0000000000001396
38
Walter Reinisch, Edouard Louis, Silvio Danese. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13Expert Review of Gastroenterology & Hepatology 2015; 9(sup1): 17 doi: 10.1586/17474124.2015.1091306
39
Vini Deora, Justin Kozak, Mohamed El‐Kalla, Hien Q. Huynh, Wael El‐Matary. Therapeutic drug monitoring was helpful in guiding the decision‐making process for children receiving infliximab for inflammatory bowel diseaseActa Paediatrica 2017; 106(11): 1863 doi: 10.1111/apa.14008
40
Johanna R. Mora, Robert Wong, Mehmooda Shaikh, Margarita Askelson. Analysis of the Immunogenicity from Abatacept‐Treated Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical TrialsACR Open Rheumatology 2022; 4(2): 177 doi: 10.1002/acr2.11375
41
Filipa Silva-Ferreira, Joana Afonso, Pedro Pinto-Lopes, Fernando Magro. A Systematic Review on Infliximab and Adalimumab Drug MonitoringInflammatory Bowel Diseases 2016; 22(9): 2289 doi: 10.1097/MIB.0000000000000855
42
Michael K Zheng, David Q Shih, Gary C Chen. Insights on the use of biosimilars in the treatment of inflammatory bowel diseaseWorld Journal of Gastroenterology 2017; 23(11): 1932-1943 doi: 10.3748/wjg.v23.i11.1932
43
Shubham Jain, Suhas Udgirkar, Qais Contractor, Pravin Rathi, Prasanta Debnath, Sujit Nair. Thiopurine-induced Myelosuppression with Severe Sepsis in a Patient with Crohn's Disease: A Case Report Indian Journal of Critical Care Medicine 2021; 25(2): 228 doi: 10.5005/jp-journals-10071-23738
44
Su-Jeong Oh, Yoojin Seo, Ji-Su Ahn, Ye Young Shin, Ji Won Yang, Hyoung Kyu Kim, Jin Han, Natalia P. Mishchenko, Sergey A. Fedoreyev, Valentin A. Stonik, Hyung-Sik Kim. Echinochrome A Reduces Colitis in Mice and Induces In Vitro Generation of Regulatory Immune CellsMarine Drugs 2019; 17(11): 622 doi: 10.3390/md17110622